Business
MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test
HALIFAX, NS / ACCESSWIRE / October 14, 2022 / Today, MedMira Inc. (MedMira) (TSXV:MIR) a...
About this update from Medmira Inc.
[{"type":"text","content":"MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen TestHALIFAX, NS / ACCESSWIRE / October 14, 2022 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of the CE mark for its VYRA™ COVID-19 Antigen Test (VYRA™ COVID-19), the fastest SARS-CoV-2 Antigen test available. The Company received the CE mark today and is now available in Europe and any countries accepting the CE mark.MedMira has utilized its patented Rapid Vertical Flow® (RVF®) technology and developed the company's first rapid antigen test, VYRA™ COVID-19 Antigen Test (VYRA™ COVID-19), designed to detect SARS-CoV-2 virus in the swab samples. VYRA CoV-2 product expands the existing COVID-19 product family and directly addresses the wishes of our customers for an equally fast, reliable, and easy-to-use testing solution. VYRA™ COVID-19 nasal swab based test is designed to be non-invasive and user-friendly, making this test more suitable for any settings.\"Whereas VYRA™ COVID-19 provides a high-quality single antigen test for the detection of SARS-CoV-2 designed for customers who are worried about a COVID-19 infection, our up-coming VYRA™ CoV2Flu Antigen Test will further complement our product offering to customers who wish to have a result for COVID-19 or Flu A or Flu B immediately.\" said Hermes Chan, CEO of MedMira Inc. \"With the increasing infection rates during the next few months and the need for quality rapid testing solutions, MedMira's VYRA™ COVID-19 is the fastest and most reliable answer. We anticipate our CE mark for the VYRA™ CoV2Flu and REVEALCOVID-19 Nab-Y Neutralising Antibody Test in the coming weeks and with it are able to offer our distribution partners a complete set of COVID-19 related products.\"About MedMiraMedMira is a leading developer and manufacturer of Rapid Vertical Flow® diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps. The Company's tests are sold globally under the REVEAL®, REVEALCOVID-19®, Multiplo® and Miriad® brands. Based on its patented Rapid Vertical Flow® Technology, MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United St...